Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01356290
Title Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Medical University of Vienna
Indications

medulloblastoma

Therapies

Thalidomide

Fenofibrate

Etoposide

Bevacizumab

Celecoxib

Cyclophosphamide + Cytarabine

Age Groups: adult | child
Covered Countries USA


No variant requirements are available.